NEWS: 公告在東京證券交易所JASDAQ標準市場新上市



Wound Care Biologics Market - Growth, Trends, and Forecasts (2020 - 2025)

出版商 Mordor Intelligence Pvt Ltd 商品編碼 921924
出版日期 內容資訊 英文 115 Pages
商品交期: 2-3個工作天內
全球傷口護理用生物製劑市場:成長,趨勢,及預測(2020年∼2025年) Wound Care Biologics Market - Growth, Trends, and Forecasts (2020 - 2025)
出版日期: 2020年08月01日內容資訊: 英文 115 Pages




第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 燒燙傷和交通事故增加的負擔
    • 傷口護理相關政府的配合
  • 市場阻礙因素
    • 治療費用高
    • 嚴格的法規指南
  • 波特的五力分析

第5章 市場區隔

  • 各產品
    • 生物皮膚替代品
    • 外用劑
  • 各創傷類型
    • 潰瘍
    • 手術、外傷
    • 燒燙傷
  • 各終端用戶
    • 醫院/診療所
    • 門診病人手術中心
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • ACell, Inc.
    • Integra LifeSciences Corporation
    • Kerecis
    • Marine Polymer Technologies, Inc.
    • MiMedx Inc.
    • MISONIX, Inc.
    • Molnlycke Health Care
    • Smith & Nephew plc
    • Wright Medical Group NV

第7章 市場機會及今後趨勢


Product Code: 67675

Wound care biologics is gaining popularity for the treatment of wounds and burn injuries. Factors, such as growing burden of burn injuries, increasing burden of diabetic foot ulcers, and government initiatives regarding wound care treatment are driving the growth of the wound care biologics market.

  • The incidence of diabetes among all ages is increasing, mainly due to obesity, unhealthy diet, and physical inactivity. According to the International Diabetes Federation, in 2019, there were around 4.2 million deaths globally due to diabetes.
  • The incidence of chronic wounds, especially foot ulcers is increasing among the diabetic population, resulting in the increased usage of wound care biologics products. Therefore, the growing focus toward the development of better treatment options, along with the huge burden of diseases, is expected to drive the wound care biologics market. However, the high treatment cost is expected to restrain the growth of the global market in the forecast period.

Key Market Trends

The Biological Skin Substitutes Segment is Expected to Witness Better Growth Over the Forecast Period

Based on products, the market is segmented into biological skin substitutes and topical agents. The biological skin substitutes segment is expected to witness better growth due to their wide usage in the treatment of chronic wounds. These skin substitutes have an intact extracellular matrix for structural support. Biological skin substitutes are majorly recommended for burn injuries and treatment of chronic wounds, such as diabetic foot ulcers and venous leg ulcers. According to the International Diabetes Federation, in 2019, almost 463 million people (20-79 years) had diabetes, and by 2045, this is expected to rise to 700 million. Chronic wounds lead to complications, such as infection, ulceration, and insufficient blood supply. Hence, the increasing burden of diabetes and the growing adoption of these products are the major factors propelling the growth of the wound care biologics market.

North America Dominates the Wound Care Biologics Market

North America is expected to dominate the wound care biologics market during the forecast years. This is mainly attributed to the growing diabetic population and the rising number of burn injury cases in the region. According to the American Burn Association, approximately 450,000 patients receive hospital and emergency room treatment for burns each year. Burn injury is one of the leading causes of unintentional death in the United States, which leads to increased adoption of wound care biologics by the hospitals or clinics. Hence, increased awareness, rapid adoption of new technologies, and increasing chronic wound cases are expected to positively impact market growth in this region.

Competitive Landscape

The wound care biologics market is competitive and many of the global players are in the market. For instance, ACell Inc., Integra LifeSciences Corporation, Kerecis, Marine Polymer Technologies Inc., MiMedx Inc., Misonix, Inc., Molnlycke Health Care, Smith & Nephew PLC, and Wright Medical Group NV are providing these products across the world.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support



  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Burn Injuries and Road Accidents
    • 4.2.2 Government Initiatives Regarding Wound Care Treatment
  • 4.3 Market Restraints
    • 4.3.1 High Treatment Cost
    • 4.3.2 Stringent Regulatory Guidelines and Challenges Faced by the Manufacturers
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Product
    • 5.1.1 Biological Skin Substitutes
    • 5.1.2 Topical Agents
  • 5.2 By Wound Type
    • 5.2.1 Ulcers
      • Diabetic Foot Ulcers
      • Venous Ulcers
      • Pressure Ulcers
      • Other Ulcers
    • 5.2.2 Surgical and Traumatic Wounds
    • 5.2.3 Burns
  • 5.3 End User
    • 5.3.1 Hospitals/Clinics
    • 5.3.2 Ambulatory Surgical Centers
    • 5.3.3 Other End Users
  • 5.4 Geography
    • 5.4.1 North America
      • United States
      • Canada
      • Mexico
    • 5.4.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.4.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • GCC
      • South Africa
      • Rest of Middle-East and Africa
    • 5.4.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 ACell Inc.
    • 6.1.2 Integra LifeSciences Corporation
    • 6.1.3 Kerecis
    • 6.1.4 Marine Polymer Technologies Inc.
    • 6.1.5 MiMedx Inc.
    • 6.1.6 MISONIX Inc.
    • 6.1.7 Molnlycke Health Care
    • 6.1.8 Smith & Nephew PLC
    • 6.1.9 Wright Medical Group NV